Oasmia Pharmaceutical AB
- ISIN SE0000722365
- Country Schweden
Company profile
Oasmia Pharmaceutical AB develops a new generation of drugs within human and veterinary oncology. The product development aims to manufacture novel formulations based on well-established cytostatics which, in comparison with current alternatives, show improved properties, a reduced side-effect profile and an expanded therapeutic area. The product development is based on in-house research within nanotechnology and company patents.
In addition to strategic investments in oncology Oasmia conducts research in infection, asthma and neurology.